Synaptiq Therapeutics Launches with SYN-001 Acquisition
Analysis based on 6 articles · First reported Jul 23, 2026 · Last updated Jul 24, 2026
The launch of Synaptiq Therapeutics and acquisition of SYN-001 is a positive development for the rare disease space, potentially creating value for investors and partners. However, as a privately held company with no immediate public market impact, the event is unlikely to significantly move broader markets.
On July 23, 2026, a consortium of European and US-based investors and Nobias Therapeutics announced the launch of Synaptiq Therapeutics, a privately held clinical-stage biotechnology company. The company was formed through the acquisition of Nobias Therapeutics' lead asset NB-001 (now SYN-001), a small molecule modulator of metabotropic glutamate receptors being developed for neuropsychiatric symptoms associated with 22q11.2 Deletion Syndrome (22q11DS). SYN-001 has received Orphan Drug Designation and Rare Pediatric Disease Designation from the US United States — Food and Drug Administration (FDA) in 2024, and preliminary alignment on registrational endpoints was announced in 2025. Founding investors include Investcorp-backed Sanos Group, Securiti, and AnBogen Therapeutics. Patrick Dougherty was appointed CEO. Synaptiq plans to initiate a Phase IIb trial across North America and Europe. Financial terms were not disclosed.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard